Aramchol Market

“Aramchol Market Size, Forecast, and Emerging Insight – 2032” report provides comprehensive insights about Aramchol for Liver fibrosis in the 7MM. A detailed picture of the Aramchol for Liver fibrosis in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the UK, and Japan, for the study period 2019–2032 is provided in this report along with a detailed description of the Aramchol for Liver fibrosis. The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the Aramchol market forecast, analysis for Liver fibrosis in the 7MM, descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about other emerging therapies in Liver fibrosis.

Drug Summary

Aramchol (arachidyl amido cholanoic acid) is a first-in-class, novel synthetic small molecule, a conjugate of cholic acid and arachidic acid, liver-targeted stearoyl-CoA desaturase 1 (SCD1) modulator, developed as an oral therapy to treat NASH and fibrosis. It can modulate hepatic lipid metabolism, which was discovered and validated in animal models, demonstrating the downregulation of the three key pathologies of NASH: steatosis, inflammation, and fibrosis. The effect of Aramchol on fibrosis is mediated by the downregulation of steatosis and acts directly on human collagen-producing cells.

Mechanism of action

Aramchol targets SCD1, the rate-limiting step in the synthesis of monounsaturated fatty acids (MUFAs), the major fatty acid of triglycerides, cholesteryl esters, and membrane phospholipids. It also increases metabolite flux through the trans-sulfuration pathway, leading to a rise in glutathione (GSH) and the GSH/glutathione disulfide (GSSG) ratio, which preserves cellular antioxidant levels and intracellular redox status.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the Aramchol description, mechanism of action, dosage and administration, research and development activities in Liver fibrosis.
• Elaborated details on Aramchol regulatory milestones and other development activities have been provided in this report.
• The report also highlights the Aramchol research and development activity in Liver fibrosis in detail across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around Aramchol.
• The report contains forecasted sales of Aramchol for Liver fibrosis till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Liver fibrosis.
• The report also features the SWOT analysis with analyst views for Aramchol in Liver fibrosis.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Aramchol Analytical Perspective by DelveInsight

In-depth Aramchol Market Assessment

This report provides a detailed market assessment of Aramchol in Liver fibrosis in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2026 to 2032.

Aramchol Clinical Assessment

The report provides the clinical trials information of Aramchol in Liver fibrosis covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights 

• In the coming years, the market scenario for Liver fibrosis is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.  
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Aramchol dominance.
• Other emerging products for Liver fibrosis are expected to give tough market competition to Aramchol and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Aramchol in Liver fibrosis.
• Our in-depth analysis of the forecasted sales data from 2026 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the Aramchol in Liver fibrosis.

Key Questions

• What is the product type, route of administration and mechanism of action of Aramchol?
• What is the clinical trial status of the study related to Aramchol in Liver fibrosis and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Aramchol development?
• What are the key designations that have been granted to Aramchol for Liver fibrosis?
• What is the forecasted market scenario of Aramchol for Liver fibrosis?
• What are the forecasted sales of Aramchol in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan? 
• What are the other emerging products available in Liver fibrosis and how are they giving competition to Aramchol for Liver fibrosis?
• Which are the late-stage emerging therapies under development for the treatment of Liver fibrosis?